VIRP Relative Valuation - Virbac SA

Watchlist Manager

Watchlist

Price: 339 EUR -1.31% Market Closed

Market Cap: €2.8B

Relative Value

The Relative Value of one VIRP stock under the Base Case scenario is hidden EUR. Compared to the current market price of 339 EUR, Virbac SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

VIRP Relative Value

Show

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
FR		Virbac SA PAR:VIRP	2.8B EUR	1.6	6	4.8	5.3
US		Eli Lilly and Co NYSE:LLY	944.6B USD	14.5	45.8	30.9	32.9
US		Johnson & Johnson NYSE:JNJ	585.1B USD	6.2	21.8	15.2	18.6
CH		Roche Holding AG SIX:ROG	262.8B CHF	4.3	20.4	12	13.5
CH		Novartis AG SIX:NOVN	233.9B CHF	5.3	21.5	13.3	17.1
UK		AstraZeneca PLC LSE:AZN	223.2B GBP	5.1	29.2	16.2	22.8
US		Merck & Co Inc NYSE:MRK	287.6B USD	4.4	15.8	9.8	11.9
IE	E	Endo International PLC LSE:0Y5F	218B USD	94	-74.6	344.9	865
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.6	10.9	8	9.4
US		Pfizer Inc NYSE:PFE	155.2B USD	2.5	20	7.7	10.2
US		Bristol-Myers Squibb Co NYSE:BMY	120.7B USD	2.5	17.1	7.2	8.9

				Revenue Growth	P/S to Growth
FR		Virbac SA PAR:VIRP	Average P/S: 13.1 1.6	6%	0.3
US		Eli Lilly and Co NYSE:LLY	14.5	19%	0.8
US		Johnson & Johnson NYSE:JNJ	6.2	6%	1
CH		Roche Holding AG SIX:ROG	4.3	4%	1.1
CH		Novartis AG SIX:NOVN	5.3	5%	1.1
UK		AstraZeneca PLC LSE:AZN	5.1	7%	0.7
US		Merck & Co Inc NYSE:MRK	4.4	5%	0.9
IE	E	Endo International PLC LSE:0Y5F	94	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.6	2%	1.8
US		Pfizer Inc NYSE:PFE	2.5	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.5	-5%	N/A

				Earnings Growth	PEG
FR		Virbac SA PAR:VIRP	Average P/E: 20.8 6	11%	0.5
US		Eli Lilly and Co NYSE:LLY	45.8	32%	1.4
US		Johnson & Johnson NYSE:JNJ	21.8	7%	3.1
CH		Roche Holding AG SIX:ROG	20.4	14%	1.5
CH		Novartis AG SIX:NOVN	21.5	14%	1.5
UK		AstraZeneca PLC LSE:AZN	29.2	26%	1.1
US		Merck & Co Inc NYSE:MRK	15.8	14%	1.1
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -74.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.9	1%	10.9
US		Pfizer Inc NYSE:PFE	20	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	17.1	16%	1.1

				EBITDA Growth	EV/EBITDA to Growth
FR		Virbac SA PAR:VIRP	Average EV/EBITDA: 42.7 4.8	8%	0.6
US		Eli Lilly and Co NYSE:LLY	30.9	22%	1.4
US		Johnson & Johnson NYSE:JNJ	15.2	2%	7.6
CH		Roche Holding AG SIX:ROG	12	6%	2
CH		Novartis AG SIX:NOVN	13.3	5%	2.7
UK		AstraZeneca PLC LSE:AZN	16.2	13%	1.2
US		Merck & Co Inc NYSE:MRK	9.8	3%	3.3
IE	E	Endo International PLC LSE:0Y5F	344.9	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8	1%	8
US		Pfizer Inc NYSE:PFE	7.7	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.2	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
FR		Virbac SA PAR:VIRP	Average EV/EBIT: 92.3 5.3	8%	0.7
US		Eli Lilly and Co NYSE:LLY	32.9	22%	1.5
US		Johnson & Johnson NYSE:JNJ	18.6	7%	2.7
CH		Roche Holding AG SIX:ROG	13.5	5%	2.7
CH		Novartis AG SIX:NOVN	17.1	9%	1.9
UK		AstraZeneca PLC LSE:AZN	22.8	21%	1.1
US		Merck & Co Inc NYSE:MRK	11.9	6%	2
IE	E	Endo International PLC LSE:0Y5F	865	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9.4	3%	3.1
US		Pfizer Inc NYSE:PFE	10.2	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.9	-7%	N/A

Virbac SA
PAR:VIRP

Relative Value

Valuation Multiples

Multiples Across Competitors

VIRP Competitors Multiples
Virbac SA Competitors

See Also

Company

Help

Tools

Stocks

Virbac SA PAR:VIRP

Relative Value

Valuation Multiples

Multiples Across Competitors

VIRP Competitors Multiples Virbac SA Competitors

See Also

Company

Help

Tools

Stocks

Virbac SA
PAR:VIRP

VIRP Competitors Multiples
Virbac SA Competitors